Clinical Trial

Pharmacokinetics and Safety Study of Levornidazole Disodium Phosphate for Injection in Subjects With Renal Impairment and Normal Renal Impairment

Completed Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the pharmacokinetics and safety of a single intravenous dose of levornidazole disodium phosphate for injection in subjects with moderate and severe renal impairment and healthy subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-13.
Trial Details
NCT Number NCT07033182
Lead Sponsor Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Collaborators: The First Affiliated Hospital of Zhengzhou University
Conditions Infections Caused by Anaerobic Bacteria, Renal Impairment
Enrollment 24 participants
Start Date 2023-10-30
Primary Completion 2024-04-07 (estimated)
Study Completion 2024-06-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-29